1 / 63

Adrenal masses – for Urology trainees

Adrenal masses – for Urology trainees. Ailsa Wilson, 2008. Exam questions. A fit patient is referred to you with a 4 cm incidental adrenal mass found on USS. Biochemical investigations reveal it to be non-functioning., Outline your management.

kamin
Download Presentation

Adrenal masses – for Urology trainees

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Adrenal masses – for Urology trainees Ailsa Wilson, 2008

  2. Exam questions • A fit patient is referred to you with a 4 cm incidental adrenal mass found on USS. Biochemical investigations reveal it to be non-functioning., Outline your management. • A 42 year old woman is referred to you with a 4 cm incidental adrenal mass. How would you evaluate this lesion? • A man aged 30 with hypertension and a 6 cm adrenal mass is sent to you. Outline your evaluation.

  3. Adrenal masses • Background: classification, incidentaloma • Adrenocortical carcinoma • Relevant endocrine pathways and syndromes: hyperaldosteronism, glucocorticoid excess, phaeochromocytoma • Investigation: • Radiology • Endocrine • Management: • Surgical (and preoperative management) • Medical

  4. Adrenal masses • Adrenocortical masses are common • O.4-6% Of CT Scans • 6.5-8.7% Of Autopsy Series • “incidentaloma”: any adrenal mass discovered by noninvasive abdominal imaging performed for reasons other than suspected adrenal disease • retrospectively often found to have had symptoms or signs related to an adrenal tumour • Incidence Increases With Age; < 1% under 30 y, 7% After 70, and as imaging increases • More Commonly In Women • Less commonly, adrenal masses are identified in workup for suspected adrenal disease • 80% adrenal masses are nonfunctioning and benign • 20% are functioning • 0.1-1% of total are malignant

  5. Adrenal masses • Main concerns with an adrenal mass are • (1) whether it is malignant • -> identify early and attempt surgical cure/directed treatment if secondary • (2) whether it is hormonally active • -> treat appropriately (surgical/medical)

  6. Classification adrenal masses • Benign • Adenomas • Functional vsNonfunctional • Haemorrhage, TB, fungal (systemic diseases that can produce adrenal insufficiency) • Malignancies • Adrenocortical carcinomas • Functional vsNonfunctional • Well differentiated vs Intermediate vs Poorly differentiated to anaplastic • Metastatic: Most commonly: Lung , Breast , Melanoma , RCC • Adrenomedullarytumors • Malignant phaeochromocytoma • Ganglioneuroblastoma • Neuroblastoma • Neuroendocrine carcinoma • Stromal malignancies : Neurofibrosarcoma ,Angiosarcoma ,Liposarcoma ,Fibrosarcoma , • Composite or mixed tumors: rare, ie, coexisting neuroblastoma and malignant phaeo • familial predisposing syndromes : Li-Fraumeni, MEN-1, Beckwith-Wiedemann

  7. Prevalence of adrenal incidentaloma • Non-hypersecretory adrenal adenoma 74-85% • Hypersecretory tumours • Cortisol secreting adenomas 9.2% • Phaeochromocytomas 4.2-10% • Aldosteronomas 1.4% • Androgen/estrogen secreting • Primary adrenal carcinoma 0.1-4% • Other adrenal masses • Myelolipoma 3-10% • Cysts 1.9-10% • Ganglioneuromas 1.5% • Haemorrhage, TB, fungal • Metastases 0.7-30% • ¾ of lesions found in patients with cancer are metastatic • 2/3 of masses in patients without a cancer diagnosis are benign • The incidental adrenal mass. Am J Med 1996

  8. 1. Is it malignant? Adrenocortical carcinoma Metastases to the adrenal

  9. Adrenocortical carcinoma • Uncommon: 0.6-1.67 cases/million/per year. • Important to distinguish potential carcinomas from other masses • female-to-male ratio 2.5-3:1. • Male -older , worse overall prognosis than female • Female -more likely to have an associated endocrine syndrome. • Nonfunctional ACs distributed equally between sexes. • 2 peaks: first decade of life and again in the fourth to fifth decades. • Most sporadic and unilateral • 2% to 6% are bilateral -associated with Li-Fraumenisynd, MEN-1, Beckwith-Wiedemannsynd, and Carney complex primarily in children • pathogenesis of sporadic AC unclear

  10. Adrenocortical carcinoma • Nonfunctional 40% • ?progress more rapidly • fever, LOW, abdo pain (infiltration, haemorrhage, necrosis), fullness, back pain, Sx related to mets or incidental finding • Functional ?60% • Detected earlier • Difficulty in discriminating adenoma from carcinoma on histology (Weiss criteria 1984) • Not all large adrenal lesions behave like carcinomas. • Some lesions that appear benign on histologic evaluation eventually metastasize. • -> FNA not useful in workup

  11. Complications of adrenal carcinoma • Complications • Local invasion, tumor thrombus can embolize similar to RCC • Hormone excess syndromes (Cushing syndrome, hyperaldosteronism, hirsutism, virilization, and hypertension) • Paraneoplastic syndromes (cachexia) • painful bone metastases • Prognosis: functional may have a better prognosis because present earlier • Poor overall 5-year survival 20-35%. • total surgical resection -> 32-47%, ?up to 70%. • Even after complete surgical resection, risk of local or distant relapse is 80% • total surgical resection not been possible-> 10-30%. • distant metastasis: 50% are dead within 12 months, 5 y survival 5%

  12. Staging for adrenal carcinoma • Sullivan et al • Tumor criteria • T1 - Tumor diameter smaller than or equal to 5 cm with no local invasion • T2 - Tumor diameter larger than 5 cm with no local invasion • T3 - Tumor of any size with local extension but not involving adjacent organs • T4 - Tumor of any size with local invasion of adjacent organs: kidney, liver, tumour extension into venous drainage of adrenals and IVC • Lymph node criteria • N0 - No regional lymph node involvement • N1 - Positive regional nodes • Metastasis criteria • M0 - No distant metastasis • M1 - Distant metastasis: most common sites lungs, liver, bone, and lymph nodes. • Stages • Stage 1 - T1, N0, M0 • Stage 2 - T2, N0, M0 • Stage 3 - T1 or T2, N1, M0 • Stage 4 - Any T, any N + M1 or T3, N1 or T4

  13. Adrenal metastasis • More common than primary adrenal carcinoma • >50% of patients with melanomas , breast, lung; • 40% of patients with RCC • Also contralateral adrenal, lymphoma, leukaemia, TCC, colon, esophagus, GB, liver, pancreas, prostate, stomach, uterus • Now identified earlier in the course of patients with cancer • Distinguishing a metastatic lesion from a primary: • Majority has history of malignancy and multiple mets • Nonfunctional • MRI pattern characteristic • FNA controversial- indicated when metastatic disease is likely, and detection would alter management.

  14. 2. Is it hormonally active?

  15. Physiology: Cortex 3 zones • ZG: mineralocorticoids • Small cells with intermediate number of lipid inclusions • ZF: glucocorticoids • Large foamy cells (lipid inclusions) • 75% of cortex • Glucocorticoids are essential for life • ZR: adrenal androgens • Compact cytoplasm, few lipid inclusions

  16. Physiology: Adrenal Cortex • common precursor used to produce series of steroid hormones • Rate limiting step for all is production of pregnenolone from cholesterol • H-P-A regulation is complex

  17. Functional tumours • Elaborate adrenal hormones (glucocorticoids, mineralocorticoids, androgens, estrogens, many other possible peptides). • Evidence of hormonal excess includes: • Cushing syndrome for cortisol-secreting adenomas • Hypertension and hypokalemia for hyperaldosteronism • Labile hypertension and spells for pheochromocytoma • Virilization in women for androgen-secreting tumors • Feminization in men for estrogen-secreting tumors

  18. Physiology: Cortex - Glucocorticoids • Control: CRH->ACTH • ant pituitary • precursor: proopiomelanocortin, also makes MSH • diurnal • 90-95% of circulating cortisol is protein bound • 7%-10% free (metabolically active) • variations in binding proteins influence total plasma cortisol value but not free cortisol

  19. Physiology: Cushing’s syndrome • symptom complex caused by excess circulating glucocorticoids • Includes: • Cushing's disease (pituitary adenoma) 70-85% • adrenal adenomas 10% • Adrenal carcinomas 8% • Micronodular hyperplasia <1% • Macronodular hyperplasia <1% • Ectopic secretion of ACTH or CRH 12% • Pseudo–Cushing's   • Major depression<1%   Alcoholism <1% • Exogenous steroids (most common) • Orth DN: Cushing's syndrome. N Engl J Med 1995;332:791.

  20. Cortisol secreting incidentalomas • Most common incidental secreting mass (5-15%) • in one study of patients with incidentalomas, 24% were found to have subclinical Cushing's syndrome. • metabolic syndrome: obesity, hypertension, dyslipidemia, impaired glucose tolerance. • may have reduced bone density and osteoporosis. • Clinical features improve after adrenalectomy • If not removed the endocrinopathycontinues • Up to 50% of incidentalomasmay have one /more slight abnormalities of H-P-A axis • (high-borderline urinary free cortisol, impaired cortisol rhythm, only partial cortisol suppression with dexamethasone, low plasma ACTH, unresponsiveness to CRH) • Adrenal insufficiency after removal of “silent” adenomas in up to 20% • Coricotrophin suppression and atrophy of contralateral gland • Partial suppression can persist for several months after adrenalectomy. • May require perioperativeglucocorticoids

  21. Physiology: Cortex - Aldosterone • Control: R-A-A, sensor in JG apparatus • main stimulus is reduced renal perfusion, renin release, • Sodium retention to attempt to restore renal perfusion • accompanied by water so isotonicity is maintained • usually gradual. Mineralocorticoid escape. • Plasma potassium also controls aldosterone release (blunted by hypokalaemia) • can result in lowering of plasma aldosterone to normal range in patients with hypokalaemia and hyperaldosteronaemia • poorly bound to albumin and plasma protein • half-life 20-30 minutes.

  22. Aldosterone producing adenoma • Rare • Most common cause of hyperaldosteronism • Twice as common in women • Mean 30-50 y • Mostly unilateral • Mostly < 2 cm • Conn (1955)—First curative treatment of APA by unilateral adrenalectomy • Difficult to control HT • Headache • Weakness/ Fatigue • Paraesthesia • Muscle Cramps • Polyuria/ Polydipsia • Arrhythmias • Hypokalemia • Metabolic Alkalosis • Hyperaldosteronism • Hyporeninemia

  23. Physiology: Adrenal Androgens (DHEA) • Control: ACTH and other mechanisms • Peripheral conversion of DHEA to DHEAS • some diurnal variation. • weakly active, in contrast to testosterone, appear relevant only in pathologic states (CAH) • not produced in significant quantities by other tissues (except occ PCOS, gonadal tumours) • Virilisation: • 5% of women with hirsutism will have have a significant adrenal pathologic process • Patients with high DHEA also have high 17-ketosteroids, virilizationcaused by elevated testosterone does not. • Elevated DHEA, androstenedione, or 17-ketosteroids out of proportion to glucocorticoids suggest adrenal carcinoma • feminisation 6%: • Virtually all feminizing adrenal tumors in men are highly malignant • gynaecomastia, infertility, low libido • Androstenedione converted peripherally to estrogens Rare as incidentalomas Many are malignant

  24. Physiology: Adrenal medulla • chromaffin cells secrete primarily adrenaline (also noradrenaline, dopamine) • PNMT catalyzes methylation of Nad -> Ad, almost localized to the medulla • high levels of glucocorticoids are necessary to maintain high levels of PNMT and Ad secretion -> location of the adrenal medulla • dietary tyrosine and phenylalanine are substrates • Catecholamines stored in vesicles • Stimulation of preganglionic sympathetic nerves (stress, pain, cold, heat, asphyxia, hypotension, hypoglycemia, and sodium depletion) -> exocytosis

  25. Physiology: Adrenal medulla • plasma half-life <20 sec • Neuronal reuptake for re-release, or degraded by COMT and MAO • primary metabolite in the urine is vanillylmandelicacid • metanephrine, normetanephrine, and their derivatives contribute to total metabolic products

  26. Physiology: Adrenal medulla • Catecholamines exert varied effects by stimulating adrenoreceptors • diversity of effects accounts for the diversity of symptoms in pheochromocytomas. • different tumors produce different proportions of Nad, Ad, or dopamine.     • if there is excessive production of both Nad and Ad, the lesion is almost always within the adrenal, not other sites of chromaffin tissue.

  27. Phaeochromocytoma • 1 in 1000 autopsies. 1-10% of incidentalomas • more common than previously thought, failure to recognize may lead to death. • Assume adrenal adenomas are phaeochromocytoma until proven otherwise • Noradrenaline secretion most common • Paroxysmal hyperadrenergicSx: headaches (80%), palpitations (64%), sweats (57%), abdominal pain. • Hypertension: Paroxysmal 48%, Persistent 29%, Normal 13% • 1981 Sutton: 25% of phaeochromocytomas found postmortem were not diagnosed antemortem (20-80% in other series) • 90% of these patients had characteristic symptoms. • Many died of causes possibly related to phaeo. 29% died unexpectedly during surgery, 27% died from cardiovascular causes, 17% died from cerebrovascular causes. • Not possible to determine the malignant potential of pheochromocytoma

  28. Functional adrenal carcinoma • Most secrete multiple compounds or nonfunctional/small volume metabolites • 50-80% are functional, especially in children • Adults: • 30-40% present with typical Cushings, • 20-30% present with virilization (overlap) – “Virilisation is the hallmark of Cushings due to carcinoma” • feminisation 6%: • aldosteronism2.5%, catecholamine excess similarly rare. • Combined hormone excess (35%), Polycythemia ( <1%), Hypercalcemia ( <1%), Hypoglycemia ( <1%) • Children: >80% present with virilization(precocious puberty) (isolated Cushings only 6%) • Ng L, Libertino JM: Adrenocortical carcinoma: Diagnosis, evaluation and treatment. J Urol 2003;169:5-11.

  29. Is an extensive diagnostic workup justified (discomfort, cost) in this particular patient?

  30. Investigation • Agreement that all patients with solid adrenal masses should undergo biochemical assessment. • If biochemical abnormalities identified, lesions should be treated—usually by removal • A selective approach limits cost without sacrificing diagnostic accuracy. • History and examination • CT/MRI • Serum and urinary cortisol (24h) to screen for Cushing's syndrome; • urine or plasma metanephrine, VMA determinations to screen for phaeochromocytoma; • (?in patients with hypertension only), serum potassium concentration and plasma renin-to-aldosterone ratio. • test recommendations have expanded since 1990 following the demonstration of more subclinical hormonal abnormalities.

  31. Investigation of adrenal masses • History • Endocrine Sx: weight gain, weakness, depression, and bruising, GI Sx • Phaeochromocytoma: episodic headaches (80%), palpitations (64%), sweats (57%), abdominal pain. • Hirsutism/feminisation, oligo/amenorrhea, and increased libido • Children: precocious puberty, weight gain, growth retardation • Malignancy: weight loss, fever • PMHx: difficult to control hypertension • Surgery • Other malignancy • CV disease, osteoporosis, obesity, diabetes • Medications: exogenous steroids, multiple antihypertensives

  32. Investigation of adrenal masses • Examination • Abdominal/flank mass • Hyper/hypotension, postural hypotension, tachycardia • Weakness, ileus • Truncal obesity, supraclavicular and dorsocervical fat pads, gynaecomastia, proximal muscle wasting • Hirsutism, facial acne, striae, malar flushing • virilization in girls, or precocity and feminization (rarely) in boys. • Fundi: hypertensive retinopathy. • Hypo/hyperglycaemia • ectopic ACTH: cachexia, hypertension, skin pigmentation, hypokalemic alkalosis • Old photographs

  33. Imaging • CT and MRI: imaging of choice • USS • Scintigraphy • PET • Angiography, venography

  34. CT • size, shape, appearance. • Targeted CT with 3-5-mm sections give best resolution esptumors ≤1 cm • Smooth, homogeneous solitary lesion <4 cm with low attenuation ie lipid rich (<10 HU) is usually benign. • Look for atrophy of the opposite gland • red flags for a possible carcinoma/metastasis • Irregular • Large size (>4 cm) • calcification • heterogeneity on plain and contrast (?intralesionalhemorrhage/necrosis) • High attenuation values (>20 HU) • invasion of local structures or extension into major vessels • lymphadenopathy • large adenomas (≥5 cm ) often share features of carcinoma

  35. Bilateral adrenal hyperplasia Adrenal adenoma

  36. MRI • as effective as CT for distinguishing benign from malignant • superior for detecting phaeochromocytomas. • nonfunctionaladenoma has a T2-weighted intensity similar to liver tissue, mild-no enhancement, rapid contrast washout. • Malignant: intermediate-to-high density on T2 imaging, rapid and intense enhancement with gadolinium contrast, with sluggish washout. • Haemorrhage, metastases and neural tumours also high density on T2 • pheochromocytomas: very high signal intensity.

  37. MRI R adrenal ca, T1 weighted image T2 weighted image – signal intensity much higher than liver or spleen

  38. Functional nuclear imaging (scintigraphy) • For lesions not adequately characterised with CT and MRI. • Not widely available, usefulness limited • [(131)I]-6-iodomethyl norcholesterol (labelled cholesterol analogue) • ?can differentiate functional adrenal cortical adenomas or functional adrenal tissue from other retroperitoneal lesions • rarely indicated in suspected AC • [(123)I]- and [(131)I]-meta-iodobenzylguanidine (labelled noradrenaline analogue) – abnormal/increased uptake in phaeochromocytomas • Excludes extraadrenal/bilateral phaeos

  39. PET and other • PET: variety of agents • can discriminate between cortical lesions and either metastatic disease or neural tumors but not between benign and malignant cortical tumors • Arteriography and venography currently have little use in diagnostic evaluation • adrenal venous sampling ie to demonstrate bilateral/unilateral hormone secretion preop • USS: less sensitivity in detecting adrenal tumors , user-dependent , Good for follow-up

  40. Hormonal workup • Initial screening: • Electrolytes: K+, Cl-, Ca2+, Na+, creatinine • Serum aldosterone and reninto compute aldosterone-to-reninratio • DHEA, testosterone • 24-hour urinary cortisoland creatinine for cortisol excretion. • 24-hour urinary catecholamines (epinephrine, norepinephrine) and metabolites (VMA, metanephrines and normetanephrines) • And then if indicated: • Low dosedexamethasone suppression test, • Serum ambulatory cortisol, ACTH • Urinary free cortisol, high dose dexamethasone suppression, others • Other serum adrenal androgens (androstenedione), 24-hour urinary 17 ketosteroids. • +/-Plasma estradiol and/or estrone, 17-hydroxyprogesterone • Urinary metanephrine-to-creatinine ratio, plasma metanephrines and catecholamines • Ross NS. Hormonal evaluation of the patient with an incidentally discovered adreanl mass.EJM 1990:323:1401-1405

  41. Glucocorticoids • establish the presence of Cushing's syndrome and to distinguish between pituitary and adrenal causes and ectopic ACTH secretion • 24-hour excretion of cortisol in the urine is the most direct and reliable • (2/3 consecutive specimens) • If normal in three collections, Cushing's syndrome is unlikely • Mildly elevated in anxiety, depression, alcoholism

  42. Glucocorticoids • Next test is the low dose dexamethasone suppression test • exclude Pseudo-Cushings or Dx subclinical Cushings • 0.5 mg orally 6 hourly for 2 days OR single 1 mg dose in evening, measure in morning • Normal: fall in plasma cortisol (<5 ng/dL) or other measures • Cushing's syndrome: resistance to suppression • Usually reserved for patients with equivocal 24-hour urinary cortisol • OR use am and pm plasma cortisol and ACTH levels . • determine the presence/absence of the normal circadian rhythm • Normal rise in morning plasma cortisol with a fall to <5 ng/dL in the evening – lost in Cushing's syndrome (or show some variations at higher basal levels) • plasma cortisol >50μg/dL and ACTH suppressed<5pg/mL=ACTH independent (primary adrenal Cushings) • plasma ACTH >50 pg/mL, the cortical secretion is ACTH dependent (pituitary or ectopic ACTH/CRH)

  43. Glucocorticoids • high-dose dexamethasone suppression test has been the standard to differentiate pituitary vs adrenal Cushing's. • dexamethasone (2 mg every 6 hours for 2 days), measure plasma cortisol, urinary free cortisol • pituitary disease,: 50% or greater suppression in cortisol. • adrenal adenomas or carcinomas :fail to suppress cortisol secretion. • Urinary free cortisol is also used as in screening (Elevated in 3.3% of lean, obese, or chronically ill patients) • late-night salivary cortisol concentration - high sensitivity, specificity • Additional tests to differentiate between pituitary overproduction ACTH (Cushing's disease) and ectopic ACTH secretion • metyraponestimulation tests • petrosalvenous sinus catheterization. • Imaging for occult ACTH-secreting tumors: CT/MRI, radionuclide imaging for somatostatinreceptors (small cell lung ca and thymic carcinoid) • CT or MRI of the sellaturcica

  44. Subclinical Cushings in incidentalomas • Because urinary free cortisol levels may be within the reference range, a dexamethasone suppression test may be needed to diagnose • some centres perform more in-depth testing (diurnal rhythm evaluation with 8 am and midnight serum or salivary cortisol estimations, CRH stimulation test, serum ACTH (generally low), and serum DHEAS (generally suppressed))

  45. Testing for primary hyperaldosteronism • *Aldosterone/PRA Ratio • ideally upright • Normal < 20 • Primary Aldosteronism> 30 (with suppressed plasma renin level and plasma aldosterone concentration >0.5 nmol/L) • > 90% Sensitivity And Specificity • aldosterone will not rise with ambulation • aldosteronenot suppressed by sodium loading (Saline Infusion test) or fludrocortisone • Urinary aldosterone excretion considered accurate also • to distinguish adenoma from idiopathic hyperaldosteronism(25%: bilateral adrenal hyperplasia) • Radiological appearance • Adrenal venous sampling - lateralisation • 18-OH-Corticosterone 􀂼 • Adenoma if >100 mg/dl -> surgery • hyperplasia if <50 ng/dl -> spironolactone • NATIONAL INSTITUTES OF HEALTH Management of the Clinically Inapparent Adrenal Mass (Incidentaloma). Final Statement. 2002

  46. Testing for androgen overproduction • Of tests of adrenal androgen function • plasma DHEA/DHEAS is more commonly used and is more accurate than androstenedionevalue. • serum testosterone • Plasma estradiol and/or estrone, 17-hydroxyprogesterone, • 24-hour urinary 17 ketosteroids.

  47. Testing for phaeochromocytoma • Urine and Plasma collection of catecholamines and metabolites • metanephrines, vanillylmandelic acid (VMA), and fractional catecholamines • Plasma free metanephrines preferred in some centres • Which Is Better? • Series of catecholamine-secreting tumors in 31 of 340 patients: • Plasma free metanephrine sensitivity 97%, Specificity 98% • Urinary total metanephrine and catecholamines sensitivity 90%; Specificity 85% • NATIONAL INSTITUTES OF HEALTH Management of the Clinically Inapparent Adrenal Mass (Incidentaloma). Final Statement, 2002 • Sawka et al. JCEM 88(2): 553-558. 2003.?

  48. FNA/core biopsy • Can’t reliably distinguish adenoma from carcinoma • histologic analysis may be unreliable, • potential for tumor seeding into the retroperitoneum. • “no role in the diagnostic workup of adrenal incidentalomas” • Generally not recommended except for possible metastatic deposits/lymphoma. • Never perform FNA without first excluding phaeochromocytoma

  49. Investigating incidentalomas

More Related